References
- Tabibian JH, O'Hara SP, Lindor KD. Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies. Scand J Gastroenterol 2014;49:901-8. https://doi.org/10.3109/00365521.2014.913189
- Bjornsson E, Olsson R, Bergquist A, Lindgren S, Braden B, Chapman RW, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 2008;134:975-80. https://doi.org/10.1053/j.gastro.2008.01.042
- Lindor KD, Kowdley KV, Harrison ME; American College of Gastroenterology. ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol 2015;110:646-59. https://doi.org/10.1038/ajg.2015.112
- Miloh T, Arnon R, Shneider B, Suchy F, Kerkar N. A retrospective single-center review of primary sclerosing cholangitis in children. Clin Gastroenterol Hepatol 2009;7:239-45. https://doi.org/10.1016/j.cgh.2008.10.019
- Feldstein AE, Perrault J, El-Youssif M, Lindor KD, Freese DK, Angulo P. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology 2003;38:210-7.
- Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50:808-14. https://doi.org/10.1002/hep.23082
- Abarbanel DN, Seki SM, Davies Y, Marlen N, Benavides JA, Cox K, et al. Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis. J Clin Immunol 2013;33:397-406. https://doi.org/10.1007/s10875-012-9801-1
- Davies YK, Cox KM, Abdullah BA, Safta A, Terry AB, Cox KL. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 2008;47:61-7. https://doi.org/10.1097/MPG.0b013e31816fee95
- Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis-a pilot study. Aliment Pharmacol Ther 2013;37:604-12. https://doi.org/10.1111/apt.12232
- Davies YK, Tsay CJ, Caccamo DV, Cox KM, Castillo RO, Cox KL. Successful treatment of recurrent primary sclerosing cholangitis after orthotopic liver transplantation with oral vancomycin. Case Rep Transplant 2013;2013:314292.
Cited by
- Role of regulatory T cells in pathogenesis and therapy of autoimmune liver disease vol.27, pp.11, 2016, https://doi.org/10.11569/wcjd.v27.i11.665
- Primary Biliary Cholangitis and Primary Sclerosing Cholangitis vol.114, pp.10, 2016, https://doi.org/10.14309/ajg.0000000000000268
- A Personalized Approach to Managing Patients With an Ileal Pouch-Anal Anastomosis vol.6, pp.None, 2016, https://doi.org/10.3389/fmed.2019.00337
- Is Bartonella a Cause of Primary Sclerosing Cholangitis? A Case Study vol.2, pp.1, 2016, https://doi.org/10.3390/gidisord2010005
- Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework vol.115, pp.6, 2016, https://doi.org/10.14309/ajg.0000000000000604
- Chronic Antibiotic-Refractory Pouchitis: Management Challenges vol.14, pp.None, 2021, https://doi.org/10.2147/ceg.s219556
- The role of oral vancomycin in inducing remission for biologic-experienced ulcerative colitis with concomitant primary sclerosing cholangitis and liver transplantation vol.14, pp.1, 2021, https://doi.org/10.1007/s12328-020-01272-8
- Assessing and managing symptom burden and quality of life in primary sclerosing cholangitis patients vol.9, pp.2, 2016, https://doi.org/10.1080/21678707.2021.1898370
- Use of oral vancomycin in children with autoimmune liver disease: A single centre experience vol.13, pp.12, 2021, https://doi.org/10.4254/wjh.v13.i12.2113